Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer

Micro-Abstract The efficacy of cabazitaxel (CAB) after abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) is unknown. Because both affect the androgen receptor (AR) there is a concern about the activity of this sequence. We retrospectively demonstrated a prostate-spe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical genitourinary cancer 2014-12, Vol.12 (6), p.428-432
Hauptverfasser:	Sella, Avishay, Sella, Tal, Peer, Avivit, Berger, Raanan, Frank, Stephen Jay, Gez, Eli, Sharide, David, Hayat, Henry, Hanovich, Ekaterina, Kovel, Svetlana, Rosenbaum, Eli, Neiman, Victoria, Keizman, Daniel
Format:	Artikel
Sprache:	eng
Schlagworte:	Abiraterone Acetate Aged Aged, 80 and over Androgen receptor Androstenes - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Chemotherapy Docetaxel and Abiraterone failure Drug Resistance, Neoplasm - drug effects Hematology, Oncology and Palliative Medicine Humans Kaplan-Meier Estimate Male Metastatic castration-resistant prostate cancer Middle Aged Prostate-Specific Antigen - blood Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - mortality Retrospective Studies Sequential therapy Taxoids - administration & dosage Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract The efficacy of cabazitaxel (CAB) after abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) is unknown. Because both affect the androgen receptor (AR) there is a concern about the activity of this sequence. We retrospectively demonstrated a prostate-specific antigen (PSA) response of 31.5%, partial response of 15.3%, and median survival of 8.2 months with CAB. CAB was active after AA and docetaxel in mCRPC.
ISSN:	1558-7673 1938-0682
DOI:	10.1016/j.clgc.2014.06.007